Clinical trial • Phase I • Endocrinology
NNC9733-0001 for Type 2 diabetes
Phase I trial of NNC9733-0001 for Type 2 diabetes. 72 participants.
Overview
- Trial Therapeutic Area
- Endocrinology
- Trial Disease
- Type 2 diabetes
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 26-08-2025
- First CTIS Authorization Date
- 24-10-2025
Trial design
Phase I trial across 1 site in Germany.
- Target Sample Size
- 72
Eligibility
Recruits 72 No vulnerable populations selected (isVulnerablePopulationSelected = false); no information provided on assent or specific consent procedures for vulnerable groups..
- Vulnerable Population
- No vulnerable populations selected (isVulnerablePopulationSelected = false); no information provided on assent or specific consent procedures for vulnerable groups.
Recruitment
- Planned Sample Size
- 72
- Recruitment Window Months
- 23
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 72
Germany
- Earliest CTIS Part Ii Submission Date
- 21-10-2025
- Latest Decision Or Authorization Date
- 24-10-2025
- Processing Time Days
- 3
- Number Of Sites
- 1
- Number Of Participants
- 72
Sites
- Site Name
- PROFIL Institut fuer Stoffwechselforschung GmbH
- Contact Person Name
- Grit Andersen
- Contact Person Email
- grit.andersen@profil.com
Sponsor
Primary sponsor
- Full Name
- Novo Nordisk A/S
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Denmark
Investigational products
- Investigational Product Name
- NNC9733-0001
Related trials
Other published trials that may interest you.